<VariationArchive VariationID="845527" VariationName="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs)" VariationType="Deletion" Accession="VCV000845527" Version="12" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-03-17" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="824250" VariationID="845527">
      <GeneList>
        <Gene Symbol="CPT2" FullName="carnitine palmitoyltransferase 2" GeneID="1376" HGNC_ID="HGNC:2330" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p32.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53196824" stop="53214197" display_start="53196824" display_stop="53214197" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53662100" stop="53679868" display_start="53662100" display_stop="53679868" Strand="+" />
          </Location>
          <OMIM>600650</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000098.3(CPT2):c.1816_1817del (p.Val606fs)</Name>
      <CanonicalSPDI>NC_000001.11:53213433:GT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p32.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="53213434" stop="53213435" display_start="53213434" display_stop="53213435" variantLength="2" positionVCF="53213433" referenceAlleleVCF="GGT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="53679106" stop="53679107" display_start="53679106" display_stop="53679107" variantLength="2" positionVCF="53679105" referenceAlleleVCF="GGT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>V583fs</ProteinChange>
      <ProteinChange>V606fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000098.2" sequenceAccession="NM_000098" sequenceVersion="2" change="c.1816_1817delGT">
            <Expression>NM_000098.2:c.1816_1817delGT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.53679106_53679107del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.53679106_53679107del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.53213434_53213435del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.53213434_53213435del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008035.1" sequenceAccession="NG_008035" sequenceVersion="1" change="g.22006_22007del">
            <Expression>NG_008035.1:g.22006_22007del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000098.3" sequenceAccession="NM_000098" sequenceVersion="3" change="c.1816_1817del" MANESelect="true">
            <Expression>NM_000098.3:c.1816_1817del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000089.1" sequenceAccession="NP_000089" sequenceVersion="1" change="p.Val606fs">
            <Expression>NP_000089.1:p.Val606fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330589.2" sequenceAccession="NM_001330589" sequenceVersion="2" change="c.1747_1748del">
            <Expression>NM_001330589.2:c.1747_1748del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001317518.1" sequenceAccession="NP_001317518" sequenceVersion="1" change="p.Val583fs">
            <Expression>NP_001317518.1:p.Val583fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="908749525" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs) AND Carnitine palmitoyltransferase II deficiency" Accession="RCV001048609" Version="8">
        <ClassifiedConditionList TraitSetID="10067">
          <ClassifiedCondition DB="MedGen" ID="C0342790">Carnitine palmitoyltransferase II deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-07" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs) AND multiple conditions" Accession="RCV002481943" Version="1">
        <ClassifiedConditionList TraitSetID="10518">
          <ClassifiedCondition DB="MedGen" ID="C1833508">Carnitine palmitoyl transferase II deficiency, myopathic form</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1833518">Carnitine palmitoyl transferase II deficiency, neonatal form</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1833511">Carnitine palmitoyl transferase II deficiency, severe infantile form</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3280160">Encephalopathy, acute, infection-induced, susceptibility to, 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-18" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs) AND Carnitine palmitoyl transferase II deficiency, severe infantile form" Accession="RCV003455207" Version="1">
        <ClassifiedConditionList TraitSetID="2467">
          <ClassifiedCondition DB="MedGen" ID="C1833511">Carnitine palmitoyl transferase II deficiency, severe infantile form</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-11" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs) AND not provided" Accession="RCV003490030" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-06-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000098.3(CPT2):c.1816_1817del (p.Val606fs) AND Encephalopathy, acute, infection-induced, susceptibility to, 4" Accession="RCV003473636" Version="1">
        <ClassifiedConditionList TraitSetID="7602">
          <ClassifiedCondition DB="MedGen" ID="C3280160">Encephalopathy, acute, infection-induced, susceptibility to, 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-07" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16996287</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17936304</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21913903</ID>
        </Citation>
        <DescriptionHistory Dated="2022-12-31">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2021-01-30">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10518" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="686" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, severe infantile form</ElementValue>
                <XRef ID="MONDO:0010914" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, HEPATIC</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, INFANTILE</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II deficiency, infantile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, infantile</ElementValue>
                <XRef ID="Carnitine+palmitoyltransferase+II+deficiency%2C+infantile/7904" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17150" />
                <XRef ID="17150" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="228305" DB="Orphanet" />
              <XRef ID="C1833511" DB="MedGen" />
              <XRef ID="MONDO:0010914" DB="MONDO" />
              <XRef Type="MIM" ID="600649" DB="OMIM" />
            </Trait>
            <Trait ID="727" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ADULT-ONSET</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, late-onset</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, myopathic form</ElementValue>
                <XRef ID="MONDO:0009704" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, MYOPATHIC</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, LATE-ONSET</ElementValue>
                <XRef Type="MIM" ID="255110" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II deficiency, myopathic, stress-induced</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, myopathic, stress-induced</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17149" />
                <XRef ID="17149" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="157" DB="Orphanet" />
              <XRef ID="228302" DB="Orphanet" />
              <XRef ID="C1833508" DB="MedGen" />
              <XRef ID="MONDO:0009704" DB="MONDO" />
              <XRef Type="MIM" ID="255110" DB="OMIM" />
            </Trait>
            <Trait ID="16567" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Encephalopathy, acute, infection-induced, susceptibility to, 4</ElementValue>
                <XRef ID="MONDO:0013633" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">IIAE4</ElementValue>
                <XRef Type="MIM" ID="614212" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18384" />
                <XRef ID="18384" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="263524" DB="Orphanet" />
              <XRef ID="C3280160" DB="MedGen" />
              <XRef ID="MONDO:0013633" DB="MONDO" />
              <XRef Type="MIM" ID="614212" DB="OMIM" />
            </Trait>
            <Trait ID="4739" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ANTENATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, lethal neonatal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, neonatal form</ElementValue>
                <XRef ID="MONDO:0012136" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, LETHAL NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, LETHAL NEONATAL</ElementValue>
                <XRef Type="MIM" ID="608836" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17151" />
                <XRef ID="17151" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="228308" DB="Orphanet" />
              <XRef ID="C1833518" DB="MedGen" />
              <XRef ID="MONDO:0012136" DB="MONDO" />
              <XRef Type="MIM" ID="608836" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7602" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16567" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Encephalopathy, acute, infection-induced, susceptibility to, 4</ElementValue>
                <XRef ID="MONDO:0013633" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">IIAE4</ElementValue>
                <XRef Type="MIM" ID="614212" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18384" />
                <XRef ID="18384" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="263524" DB="Orphanet" />
              <XRef ID="C3280160" DB="MedGen" />
              <XRef ID="MONDO:0013633" DB="MONDO" />
              <XRef Type="MIM" ID="614212" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10067" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6221" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyl transferase 2 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyltransferase II deficiency</ElementValue>
                <XRef ID="MONDO:0015515" DB="MONDO" />
                <XRef ID="238002005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase deficiency type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CPT2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1121" />
                <XRef ID="1121" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="157" DB="Orphanet" />
              <XRef ID="C0342790" DB="MedGen" />
              <XRef ID="MONDO:0015515" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="686" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carnitine palmitoyl transferase II deficiency, severe infantile form</ElementValue>
                <XRef ID="MONDO:0010914" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II DEFICIENCY, HEPATIC</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT2 DEFICIENCY, INFANTILE</ElementValue>
                <XRef Type="MIM" ID="600649" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CPT II deficiency, infantile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carnitine palmitoyltransferase II deficiency, infantile</ElementValue>
                <XRef ID="Carnitine+palmitoyltransferase+II+deficiency%2C+infantile/7904" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17150" />
                <XRef ID="17150" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.</Attribute>
                <XRef ID="NBK1253" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301431</ID>
                <ID Source="BookShelf">NBK1253</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="228305" DB="Orphanet" />
              <XRef ID="C1833511" DB="MedGen" />
              <XRef ID="MONDO:0010914" DB="MONDO" />
              <XRef Type="MIM" ID="600649" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4114743" SubmissionDate="2022-03-11" DateLastUpdated="2022-03-12" DateCreated="2022-03-12">
        <ClinVarSubmissionID localKey="NM_000098.2:c.1816_1817delGT|MedGen:C0342790" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002103336" DateUpdated="2022-03-12" DateCreated="2022-03-12" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16996287</ID>
          </Citation>
          <Comment>Variant summary: CPT2 c.1816_1817delGT (p.Val606LeufsX2) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic via ClinVar (p.Glu645Argfs*5). The variant was absent in 251492 control chromosomes. c.1816_1817delGT has been reported in the literature in an individual affected with Carnitine Palmitoyltransferase II Deficiency (Isackson_2006). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.2:c.1816_1817delGT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342790" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11183486</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5437859" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000098.3:c.1816_1817del|OMIM:255110;600649;608836;614212" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002790235" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.3:c.1816_1817del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="255110" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="600649" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608836" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614212" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7817020" SubmissionDate="2023-12-17" DateLastUpdated="2023-12-24" DateCreated="2023-12-24">
        <ClinVarSubmissionID localKey="NM_000098.3:c.1816_1817del|OMIM:600649" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004178316" DateUpdated="2023-12-24" DateCreated="2023-12-24" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.3:c.1816_1817del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="600649" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14095410</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7866987" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000098.3:c.1816_1817del|OMIM:614212" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004211041" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.3:c.1816_1817del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614212" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7911157" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2024-02-04">
        <ClinVarSubmissionID localKey="2c9aaba86b9b79d0155cbb050d4a8ca51eae15121ee54ccd68f2a7d9e4961abf|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004235429" DateUpdated="2024-02-04" DateCreated="2024-02-04" Type="SCV" Version="1" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000098.3:c.1816_1817del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2377975" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="2191190|MedGen:C0342790" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001212623" DateUpdated="2024-02-20" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16996287</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17936304</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21913903</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val606Leufs*2) in the CPT2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 53 amino acid(s) of the CPT2 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with adult onset carnitine palmitoyltransferase II (CPT II) deficiency (PMID: 16996287). ClinVar contains an entry for this variant (Variation ID: 845527). This variant disrupts a region of the CPT2 protein in which other variant(s) (p.Glu645Argfs*5) have been determined to be pathogenic (PMID: 17936304, 21913903). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CPT2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.53679106_53679107del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342790" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5437859" TraitType="Disease" MappingType="XRef" MappingValue="600649" MappingRef="OMIM">
        <MedGen CUI="C1833511" Name="Carnitine palmitoyl transferase II deficiency, severe infantile form" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437859" TraitType="Disease" MappingType="XRef" MappingValue="255110" MappingRef="OMIM">
        <MedGen CUI="C1833508" Name="Carnitine palmitoyl transferase II deficiency, myopathic form" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2377975" TraitType="Disease" MappingType="XRef" MappingValue="C0342790" MappingRef="MedGen">
        <MedGen CUI="C0342790" Name="Carnitine palmitoyltransferase II deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437859" TraitType="Disease" MappingType="XRef" MappingValue="608836" MappingRef="OMIM">
        <MedGen CUI="C1833518" Name="Carnitine palmitoyl transferase II deficiency, neonatal form" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4114743" TraitType="Disease" MappingType="XRef" MappingValue="C0342790" MappingRef="MedGen">
        <MedGen CUI="C0342790" Name="Carnitine palmitoyltransferase II deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7911157" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5437859" TraitType="Disease" MappingType="XRef" MappingValue="614212" MappingRef="OMIM">
        <MedGen CUI="C3280160" Name="Encephalopathy, acute, infection-induced, susceptibility to, 4" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7866987" TraitType="Disease" MappingType="XRef" MappingValue="614212" MappingRef="OMIM">
        <MedGen CUI="C3280160" Name="Encephalopathy, acute, infection-induced, susceptibility to, 4" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7817020" TraitType="Disease" MappingType="XRef" MappingValue="600649" MappingRef="OMIM">
        <MedGen CUI="C1833511" Name="Carnitine palmitoyl transferase II deficiency, severe infantile form" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

